Supplementary file 1_Comparative effectiveness of CDK4/6 inhibitor plus endocrine therapy

From January 2019 to November 2023, a retrospective study at Tianjin Medical University Cancer Institute and Hospital enrolled 341 patients with HR+/HER2- metastatic breast cancer. The dataset, authored by Yan Jia, compares the progression-free survival, objective response rate, and clinical benefit rate of three CDK4/6 inhibitors combined with endocrine therapy.

Use Cases

• Compare progression-free survival (PFS) outcomes for palbociclib, abemaciclib, and dalpiciclib based on the reported median PFS values.
• Analyze objective response rate (ORR) and clinical benefit rate (CBR) differences between aromatase inhibitors and fulvestrant combinations.
• Investigate the relationship between treatment efficacy and key molecular biomarkers mentioned in the study.
• Model survival outcomes using the provided follow-up durations and event data for the three drug groups.

Strengths

• Includes 341 patient records from a defined clinical cohort.
• Reports specific median PFS values (e.g., 25.3 months for palbociclib) and follow-up durations for three drug groups.
• Provides objective response rates with 95% confidence intervals for each treatment combination.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect geographic bias inherent to the single-center study in China.

Provenance

Source

Tianjin Medical University Cancer Institute and Hospital, China.

Collection Method

Retrospective, observational, single-center analysis.

Time Range

January 1, - November 1, 2023.

Freshness

Last updated 2026-04-13 08:15:44; freshness should be verified.

Geography

China.